RxDoctor Payments Data

Bernardo Lucena, MD

Internal Medicine · Crown Point, INNPI 1356391676

Payments from drug & device makers

$618in general payments, 2019–2025

Across 34 payments — averaging $18.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$139
  • Amgen$107
  • Takeda Pharmaceuticals U.S.A., Inc.$104
  • Boehringer Ingelheim$62
  • Novo Nordisk$52
  • Astellas Pharma US Inc$23
  • plus $131 from 8 others

What the payments were for

  • Food & beverage$57393%
  • Education$457%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$618 in reported general payments places this provider in the 70th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$175,343
Medicare patients
238
Services billed
2,429

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban120$63,442
JardianceEmpagliflozin61$54,526
RybelsusSemaglutide17$43,601
XareltoRivaroxaban62$36,701
OzempicSemaglutide25$30,213
MounjaroTirzepatide27$29,701
JanuviaSitagliptin Phosphate44$17,495
Breo ElliptaFluticasone/Vilanterol34$17,471
LinzessLinaclotide18$15,393
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$12,834
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog21$10,215
EntrestoSacubitril/Valsartan16$9,896
Janumet XrSitagliptin Phos/Metformin Hcl12$6,764
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/712$6,756
Glucagon Emergency KitGlucagon14$5,004

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic, Novolog$52$75,59755 claims
PfizerEliquis$13$63,442120 claims
Boehringer IngelheimJardiance$62$54,52661 claims
GSKBreo Ellipta, Trelegy Ellipta$11$30,30548 claims
Lilly USA, LLCMounjaro$139$29,70127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in Crown Point

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →